FDA approves subcutaneous formulation of Actemra for use in active polyarticular juvenile idiopathic arthritis (pJIA), a rare form of juvenile arthritis

Roche announced today that the US Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra ® (tocilizumab) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients two years of age and older.

https://www.roche.com/investors/updates/inv-update-2018-05-15.htm

Source: Roche Investor Update - May 15, 2018 Category: Pharmaceuticals Source Type: news

More News: Actemra | Arthritis | Food and Drug Administration (FDA) | Pharmaceuticals | Rheumatology